Jazz Pharma Sets IPO Terms

Jazz Pharmaceuticals Inc., a Palo Alto, Calif.-based drug development and commercialization company focused on neurology and psychiatry, has set its proposed IPO terms to six million common shares being offered at between $24 and $26 per share. It plans to trade on the Nasdaq under ticker symbol JAZZ, with Morgan Stanley and Lehman Brothers serving as co-lead underwriters. The company has raised around $265 million in VC funding since its 2003 inception, from firms like KKR (46.24% pre-IPO stake), Thoma Cressey Equity Partners (10.72%), Beecken Petty O'Keefe & Co. (7.15%), Prospect Venture Partners (6.65%), Versant Ventures (6.65%), Golden Gate Capital (5.36%), Lehman Brothers (5.13%), Adams Street Partners, EGS Healthcare Capital Partners and Oak Hill Capital. www.orphan.com